Simvastatin with or without ezetimibe in familial hypercholesterolemia

Area of Science:

• Cardiology
• Pharmacology
• Medical Research

Background:

• Ezetimibe inhibits cholesterol absorption and lowers LDL cholesterol when combined with statins.
• The impact of ezetimibe on atherosclerosis progression is not well understood.

Purpose of the Study:

• To evaluate the effect of ezetimibe combined with simvastatin on atherosclerosis progression.
• To compare combined therapy with simvastatin monotherapy in patients with familial hypercholesterolemia.

Main Methods:

• A 24-month, double-blind, randomized trial involving 720 familial hypercholesterolemia patients.
• Comparison of daily simvastatin (80 mg) with placebo versus simvastatin (80 mg) plus ezetimibe (10 mg).
• Assessment of intima-media thickness (IMT) in carotid and femoral arteries via B-mode ultrasonography.

Main Results:

• No significant difference in mean carotid artery IMT change between simvastatin-only and combined therapy groups (P=0.29).
• Combined therapy significantly reduced LDL cholesterol (16.5% lower), triglycerides, and C-reactive protein compared to simvastatin alone (P<0.01).
• Similar side-effect and safety profiles were observed in both groups.

Conclusions:

• Combined ezetimibe and simvastatin therapy did not significantly alter intima-media thickness progression compared to simvastatin alone.
• Despite improved lipid profiles and reduced C-reactive protein, ezetimibe did not provide additional benefit in slowing atherosclerosis progression in this patient group.